Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib vs Irinotecan in ALTRK-negative ESCC
NCT05818982Phase 2Recruiting
- Sponsor
- Peking University
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Started Feb 2023; status: recruiting.
02
Drugs
afatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05818982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818982.